2025-07-22 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data, formatted as requested.

## JNJ Stock Analysis (July 22, 2025)

**Ticker:** JNJ
**Company Name:** Johnson & Johnson

**Overview:** Johnson & Johnson is a global healthcare company engaged in the research, development, manufacture, and sale of a broad range of products in the healthcare field.

---

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 21.08%
*   **VOO Cumulative Return:** 97.07%
*   **Absolute Difference:** -76.1%

**Deviation Analysis:**

*   **Range:** -83.0 to 20.0
*   **Current Deviation:** -76.1
*   **Relative Deviation:** 6.7

**Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) over the analyzed period. The relative deviation of 6.7 suggests JNJ's underperformance is near its historical worst compared to the S&P 500 within the provided data.

**Alpha, Beta & Risk Metrics:**

| Year       | CAGR    | MDD     | Alpha     | Beta   | Cap(B) |
|------------|---------|---------|-----------|--------|--------|
| 2015-2017  | 28.0%   | 56.1%   | -1.0%     | -0.0   | 336.2  |
| 2016-2018  | 8.0%    | 56.6%   | -10.0%    | 0.0    | 310.5  |
| 2017-2019  | 18.0%   | 56.6%   | -12.0%    | 0.7    | 351.0  |
| 2018-2020  | 12.0%   | 59.2%   | -8.0%     | 0.3    | 378.7  |
| 2019-2021  | 32.0%   | 59.6%   | -16.0%    | 0.2    | 411.6  |
| 2020-2022  | 7.0%    | 61.4%   | 5.0%      | 0.2    | 425.0  |
| 2021-2023  | -15.0%  | 61.4%   | -33.0%    | 0.4    | 377.1  |
| 2022-2024  | -35.0%  | 61.4%   | -61.0%    | 0.3    | 348.0  |
| 2023-2025  | -6.0%   | 70.1%   | -55.0%    | 0.2    | 395.5  |

**Analysis:** This table provides rolling 3-year performance metrics. Key observations:

*   **CAGR:**  CAGR is highly variable, with negative values for recent periods (2021-2025), indicating poor recent performance.
*   **MDD:**  Maximum Drawdown remains relatively high, indicating significant potential for loss.
*   **Alpha:**  Alpha is consistently negative, especially in recent periods, suggesting JNJ has underperformed its benchmark after accounting for risk.
*   **Beta:** Beta values are generally low (close to zero), which implies the stock is not strongly correlated with the market and is less sensitive to market movements.

### 2. Recent Price Action

*   **Current Price:** 164.36
*   **Previous Close:** 163.7
*   **Change:** 0.4
*   **5-Day Moving Average:** 162.198
*   **20-Day Moving Average:** 156.5132
*   **60-Day Moving Average:** 154.7393

**Analysis:** The current price shows a slight increase from the previous close. The price is above its 5, 20, and 60-day moving averages, suggesting a short-term upward trend.

### 3. Technical Indicators & Outlook

*   **Market Risk Indicator (MRI):** 0.3383 (Low Risk)
*   **RSI:** 76.03 (Overbought)
*   **PPO:** 0.64
*   **Hybrid Signal:** Cash 0%, Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Delta Previous Relative Divergence (20-day):** 3.7 (+) - Short-term increase
*   **Expected Return:** -418.9%

**Analysis:**

*   **MRI:** The MRI indicates low market risk.
*   **RSI:** The high RSI value suggests the stock is currently overbought and may be due for a correction.
*   **PPO:** The positive PPO value indicates that the shorter-term moving average is above the longer-term moving average, confirming the upward trend.
*   **Hybrid Signal:** The hybrid signal recommends buying a limited number of shares, but with caution, likely due to the low MRI but high RSI.
*   **Relative Divergence:**  The positive change in relative divergence confirms a recent upward trend.
*   **Change**: The price change (0.4) suggests no significant market volatility based on previousClose(163.7).
*   **Expected Return:** The very negative expected return suggests a poor long-term outlook for JNJ compared to the S&P 500, if investing today.

### 4. Recent News & Significant Events

*   **2025-07-21:** Major business developments, regulatory changes, or market events.
*   **2025-07-20:** Analyst discussions on recent performance and outlook.
*   **2025-07-18:** Notable stock volatility.
*   **2025-07-19:** Market experts highlight risks and opportunities.

**Analysis:** The news indicates recent volatility and attention surrounding JNJ, likely related to business events and analyst outlook.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-04-23 | 4.57 | 21.89 B$  |
| 2024-10-23 | 1.12 | 22.47 B$  |
| 2024-07-25 | 1.95 | 22.45 B$  |
| 2024-05-01 | 1.35 | 21.38 B$  |
| 2025-04-23 | 1.35 | 21.38 B$  |

**Analysis:** Earnings per share (EPS) shows variability across the reported quarters. The revenue has fluctuated within a relatively narrow range.  There is a duplicate entry for 2025-04-23, which should be corrected.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|---------------|
| 2025-03-31   | $21.89B     | 66.40%         |
| 2024-12-31   | $22.52B     | 68.35%         |
| 2024-09-30   | $22.47B     | 69.01%         |
| 2024-06-30   | $22.45B     | 69.40%         |
| 2024-03-31   | $21.38B     | 69.55%         |

**Capital and Profitability:**

| Quarter      | Equity      | ROE     |
|--------------|-------------|---------|
| 2025-03-31   | $78.11B     | 14.08%  |
| 2024-12-31   | $71.49B     | 4.80%   |
| 2024-09-30   | $70.16B     | 3.84%   |
| 2024-06-30   | $71.54B     | 6.55%   |
| 2024-03-31   | $70.02B     | 4.65%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue is relatively stable. Profit margins have slightly decreased over the observed period.
*   **Capital and Profitability:** Equity has increased significantly in the most recent quarter (2025-03-31).  ROE is volatile, with a very large increase in the most recent quarter.

### 7. Overall Assessment

**Summary:**

Johnson & Johnson (JNJ) is currently showing mixed signals.

*   **Underperformance:**  It has significantly underperformed the S&P 500 historically.
*   **Recent Trend:**  There's a recent short-term upward price trend.
*   **Technicals:**  The RSI indicates an overbought condition, suggesting a potential pullback. The MRI suggests low overall market risk.
*   **Financials:** Revenue is stable, but profit margins are slightly declining. The most recent quarter shows a significant increase in both equity and ROE.
*   **News:** Recent news indicates increased activity and volatility.
*   **Expected Return:** The expected return is very negative, indicating a poor long-term outlook for investors at the present time.

**Conclusion:**

Based on this data, JNJ appears to be a risky investment currently.  The historical underperformance relative to the S&P 500, the overbought RSI, and the negative expected return are all cause for concern. While there are some positive short-term trends and recent improvements in equity and ROE, investors should proceed with caution and conduct thorough due diligence before investing. The news indicating volatility and activity around the stock should also be closely monitored.
